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OBJECTIVES The study examined whether patients with Brugada syndrome are sensitive to vagal
stimulation or ischemia.
BACKGROUND Experimental studies have suggested that a prominent transient outward current (Ito)-
mediated action potential notch and a subsequent loss of the action potential dome in the
epicardium, but not in the endocardium, give rise to ST-segment elevation and subsequent
ventricular fibrillation (VF).
METHODS We evaluated the frequency of coronary spasm, augmentation (0.1 mV) of ST-segment
elevation in leads V1 to V3, and induction of VF by intracoronary injection of acetylcholine
(ACh) and/or ergonovine maleate (EM) in 27 symptomatic patients with Brugada syndrome
and 30 control subjects.
RESULTS The coronary spasm was induced in 3 (11%) of the 27 patients with Brugada syndrome and
in 13 (43%) of the 30 control subjects. ST-segment elevation was augmented by 11 (33%) of
the 33 right coronary injections (ACh: 6/11 [55%]; EM: 5/22 [23%]), without coronary
spasm, but not by any of the left coronary injections in patients with Brugada syndrome.
Ventricular fibrillation was induced by 3 (9%) of the 33 right coronary injections (ACh: 2/11
[18%]; EM: 1/22 [5%]), but not by any of the left coronary injections. In contrast, neither
ST-segment elevation nor VF was observed in any of the control subjects.
CONCLUSIONS Our results support the hypothesis that mild ischemia and vagal influences act additively or
synergistically with the substrate responsible for the Brugada syndrome to elevate the ST-
segment and precipitate VF. These observations suggest that Brugada patients may be at a
higher risk for ischemia-related sudden death. (J Am Coll Cardiol 2002;40:1841–7) © 2002
by the American College of Cardiology Foundation
In 1992, Brugada and Brugada (1) reported eight patients
with a distinct electrocardiographic (ECG) pattern, consist-
ing of right bundle branch block (RBBB) with peculiar
ST-segment elevation in the right precordial leads (V1 to
V3) and sudden cardiac death in the absence of any
structural heart disease. Patients with these peculiar ECG
abnormalities and documented ventricular fibrillation (VF)
have been recognized as a subgroup (i.e., Brugada syn-
drome), and their clinical manifestations have been de-
scribed (2–5).
Vasospastic angina is another etiology of VF in patients
without identifiable structural heart disease and should be
excluded to confirm the diagnosis of Brugada syndrome
(6–8). However, coexistence of Brugada syndrome and
vasospastic angina has recently been reported in a couple of
case reports (9–11).
Recent experimental studies have suggested that a prom-
inent transient outward current (Ito)-mediated action po-
tential notch and a subsequent loss of the action potential
dome in epicardial cells, but not in endocardial cells, in the
right ventricular outflow tract (RVOT), give rise to voltage
gradients across the ventricular wall, resulting in ST-
segment elevation in the right precordial leads and subse-
quent VF due to the mechanism of phase 2 reentry (12,13).
Because the maintenance of the action potential dome is
determined by the balance of inward and outward currents
active at the end of phase 1 of the action potential, any
agents that cause an outward shift (e.g., increase in Ito,
increase in adenosine triphosphate–sensitive potassium cur-
rent [IKATP], decrease in calcium current [ICa], decrease in
fast sodium current [INa]) can increase the magnitude of the
action potential notch, leading to the ST-segment elevation
and VF in patients with Brugada syndrome (14). Therefore,
we hypothesized that the increase in IKATP and/or decrease
in ICa may enhance the ST-segment elevation in the right
precordial leads and induce VF in patients with Brugada
syndrome, secondary to ischemia or vagomimetic action by
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intracoronary injection of acetylcholine (ACh) and/or er-
gonovine maleate (EM), especially by injection to the right
coronary artery, which perfuses to the RVOT.
The present study was designed to examine this hypoth-
esis, as well as to systematically evaluate the frequency of
coexistence of Brugada syndrome and vasospastic angina.
METHODS
Patient characteristics. The study population included 27
consecutive patients affected with symptomatic Brugada
syndrome who were admitted to the National Cardiovascu-
lar Center, Osaka, Japan, between 1992 and 2001. There
were 26 men and 1 woman ranging in age from 21 to 63
years (mean 47  13). All 27 patients had episodes of
syncope without any prodrome, including chest pain, or a
history of aborted cardiac arrest with or without documen-
tation of VF. In all patients, a physical examination, chest
roentgenogram, laboratory values, echocardiographic study
with wall motion analysis and Doppler screening, and
cardiac catheterization with left and right ventriculography
were performed or obtained, and no structural heart disease
was found. The patients also fulfilled the following criteria
(15,16): 1) spontaneously documented persistent or tran-
sient ST-segment elevation (coved or saddle-back type) in
the right precordial leads V1 to V3 with or without some
degree of RBBB; and 2) a corrected QT interval 440 ms.
The control group consisted of 30 randomly selected sub-
jects; all were men ranging in age from 38 to 75 years (mean
60  11) who had chest pain or chest discomfort and were
suspected of having vasospastic angina. There were four
patients with incomplete RBBB (QRS duration 100 to
120 ms) and two with complete RBBB (QRS duration
120 ms).
Coronary angiography and administration of ACh
and/or EM. All protocols were reviewed and approved by
our Ethical Review Committee, and written, informed
consent was obtained from all patients. Before coronary
angiography, all drugs, including nitroglycerin and Ca2
antagonists, were discontinued for at least five half-lives of
each drug. The patients were in the supine resting state and
underwent coronary angiography by the Judkins technique.
The left coronary angiograms in the right anterior oblique
projection and the right coronary angiograms in the left
anterior oblique projection were obtained in the baseline
condition without injection of nitroglycerin, in a standard
manner. An electrode catheter was positioned in the right
ventricular apex and connected to a pacemaker for backup
pacing (40 beats/min). We first injected ACh, which was
diluted in 10 ml of 0.9% saline and was raised to 37°C, into
the right coronary artery and then into the left coronary
artery. Acetylcholine was injected over 20 s in incremental
doses of 20 and 50 g within a 2-min interval. We injected
EM into the right coronary artery and then into the left
coronary artery in incremental doses of 10, 20, and 40 g in
the same manner. The EM study was performed at least 10
min after the completion of the ACh injection. In the 27
patients with Brugada syndrome, ACh alone was injected in
6 patients, EM alone in 15 patients, and both ACh and EM
in the remaining 6 patients (Patient # 22 to 27) (Table 1).
In the 30 control subjects, ACh alone was injected 6
patients and EM alone in 24 patients. Arterial blood
pressure and the 12-lead ECG were continuously moni-
tored before and after injection of ACh or EM. Coronary
angiography was performed to observe the presence or
absence of coronary spasm and whether the patients had
chest discomfort, the ST segment was elevated or depressed
in any leads, or the injection of the maximal dose of ACh or
EM to each coronary artery was complete. If coronary spasm
was induced but was not resolved spontaneously, 200 g
nitroglycerin was injected into the coronary artery with spasm.
Analysis of parameters. We evaluated the frequency of
induction of coronary artery spasm, augmentation of ST-
segment elevation in the right precordial leads, and induc-
tion of VF. Coronary artery spasm was assessed at total or
near-total occlusion focally. Augmentation of ST-segment
elevation in leads V1 to V3 was defined as an increase of
0.1 mV in the amplitude of the ST segment 20 ms after
the end of the QRS complex in lead V1, V2, or V3 after
injection of ACh or EM.
RESULTS
Clinical characteristics. Table 1 shows the clinical char-
acteristics of the 27 patients with Brugada syndrome. In the
baseline condition, 9 patients with Brugada syndrome
showed a normal QRS duration, 10 patients had incomplete
RBBB, and 8 patients exhibited complete RBBB. All
patients had episodes of syncope, and 14 patients had a
history of aborted cardiac arrest. Ventricular fibrillation was
documented in 14 patients, and 4 patients had family
members who died suddenly.
Induction of coronary artery spasm. There was no signif-
icant organic stenosis of the right and left coronary arteries
in the baseline condition in both groups. Coronary spasm
was induced in 3 (11%) of the 27 patients with Brugada
syndrome. Right coronary spasm (segment no. 1, 100%) was
induced by the right coronary injection of ACh in one
patient. Left coronary spasm was induced by the left
Abbreviations and Acronyms
ACh  acetylcholine
ECG  electrocardiogram or electrocardiographic
EM  ergonovine maleate
ICa  calcium current
IKATP  adenosine triphosphate–sensitive potassium
current
INa  sodium current
Ito  transient outward current
RBBB  right bundle branch block
RVOT  right ventricular outflow tract
VF  ventricular fibrillation
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coronary injection of ACh in one patient (segment no. 7,
90%) and by the same injection of EM in the remaining one
patient (segment no. 6, 99%). In contrast, coronary spasm
was induced by 4 of 6 ACh injections and by 9 of 24 EM
injections in the control subjects (Table 2).
Augmentation of ST-segment elevation in the right
precordial leads. Figure 1 shows the 12-lead ECG before
and after ACh injection into the right coronary artery in a
patient with Brugada syndrome. The baseline ECG shows
coved or saddle-back type ST-segment elevation in leads V1
and V2 (Fig. 1A). Injection of 50 g ACh augmented the
ST-segment elevation in leads V1 and V2, without any
induction of coronary spasm (Fig. 1B), leading to sponta-
neously induced VF (Fig. 1C). Figure 2 illustrates the
12-lead ECG before and after EM injection into the right
coronary artery in a control subject. In this case, injection of
40 g EM produced spasm of the right coronary artery
(segment no. 2, 75%; segment no. 4, 100%), associated with
ST-segment elevation in leads II, III, and aVF. However,
no ST-segment elevation was observed in leads V1 to V3,
like that in the patient with Brugada syndrome (Fig. 2B). In
the patients with Brugada syndrome, the ST-segment
elevation in leads V1 to V3 was augmented by 6 (55%) of 11
right coronary injections of ACh and by 5 (23%) of 22 right
coronary injections of EM, and this was not associated with
any induction of coronary spasm. It is noteworthy that the
augmentation of ST-segment elevation localized in leads V1
to V3 was never induced by the left coronary injection of
ACh or EM. ST-segment elevation in leads V1 to V3 was
Table 1. Clinical and Electrocardiographic Characteristics in the 27 Patients With
Brugada Syndrome
Pt.
No.
Age
(yrs) Gender
Documented
VF
Aborted
CA FH
ECG Findings During SR
RBBB QRS (ms) QTc (ms)
1 47 M    IRBBB 110 413
2 48 M    IRBBB 110 386
3 20 M    — 70 408
4 51 M    IRBBB 110 422
5 46 M    — 70 412
6 21 M    — 80 398
7 38 M    — 90 362
8 48 M    CRBBB 140 415
9 27 M    — 70 371
10 63 M    CRBBB 140 386
11 47 M    CRBBB 120 366
12 42 M    CRBBB 140 421
13 52 M    IRBBB 110 413
14 57 M    CRBBB 120 404
15 45 M    IRBBB 110 402
16 41 M    CRBBB 140 419
17 29 M    IRBBB 100 410
18 61 M    — 80 362
19 63 M    — 70 367
20 57 M    CRBBB 130 398
21 39 M    IRBBB 110 408
22 51 M    — 70 402
23 49 M    IRBBB 110 384
24 72 M    IRBBB 100 402
25 42 M    — 70 367
26 61 M    CRBBB 130 419
27 51 F    IRBBB 100 412
MeanSD 47  13 104  25 397  20
CA  cardiac arrest; CRBBB  complete right bundle branch block; ECG  electrocardiographic; F  female; FH  family
history; IRBBB  incomplete right bundle branch block; M  male; QRS  QRS duration; QTc  corrected QT interval;
RBBB  right bundle branch block; SR  sinus rhythm; VF  ventricular fibrillation;   present;   absent.
Table 2. Frequency of Induction of Coronary Spasm,
Augmentation of ST-Segment Elevation, and Induction of
Ventricular Fibrillation
Brugada Group
(n  27;
33 Injections)
Control Group
(n  30;
30 Injections)
Induction of coronary spasm
ACh 2/11 (18%) 4/6 (67%)
EM 1/22 (5%) 9/24 (38%)
Total 3/33 (9%) 13/30 (43%)
Augmentation of ST-segment
elevation
ACh 6/11 (55%) 0/6 (0%)
EM 5/22 (23%) 0/24 (0%)
Total 11/33 (33%) 0/30 (0%)
Induction of VF
ACh 2/11 (18%) 0/6 (0%)
EM 1/22 (5%) 0/24 (0%)
Total 3/33 (9%) 0/30 (0%)
ACh  acetylcholine; EM  ergonovine maleate; VF  ventricular fibrillation.
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not observed by either ACh or EM injection in any of the
control subjects (Table 2).
Induction of VF. In the patients with Brugada syndrome,
VF was induced by 2 (18%) of the 11 right coronary
injections of ACh and by 1 (5%) of 22 right coronary
injections of EM, and this was not associated with any
induction of coronary spasm. Ventricular fibrillation was not
induced by the left coronary injection of ACh or EM. In
contrast, VF did not occur in any of the control subjects
(Table 2).
Acetylcholine versus EM. The frequency of augmentation
of ST-segment elevation in leads V1 to V3 and VF induction
was evaluated in six patients with Brugada syndrome in
whom both ACh and EM were used. No coronary spasm
was induced by either ACh or EM in these patients. Figure
3 shows the 12-lead ECG of a patient with Brugada
syndrome with injection of both ACh and EM. The
baseline ECG shows coved and saddle-back type ST-
segment elevation in leads V1 and V2 (Fig. 3A). ST-
segment elevation was augmented by the right coronary
injection of 50 g ACh, without any induction of coronary
spasm (Fig. 3B), but not by the right coronary injection of
40 g EM (Fig. 3C). Once again, the augmentation of
ST-segment elevation in leads V1 to V3 was never induced
by the left coronary injection of either ACh or EM.
ST-segment elevation in leads V1 to V3 was augmented by
four of six injections of ACh, but by only one of six
injections of EM. Ventricular fibrillation was induced by
one of six right coronary injections of ACh (Table 3).
DISCUSSION
Brugada syndrome and vasospastic angina. Brugada syn-
drome is characterized by a peculiar ST-segment elevation
in leads V1 to V3 and an episode of VF in the absence of any
structural heart disease (1–5). ST-segment elevation in any
ECG lead reflecting the ischemic region and subsequent VF
are also observed in patients with vasospastic angina but no
structural heart disease (6–8). Therefore, vasospastic angina
must be excluded to diagnose the patient with Brugada
syndrome. However, some case reports have demonstrated
the combination of Brugada syndrome and vasospastic
angina simultaneously (9–11). The present study systemat-
ically evaluated the incidence of induced coronary spasm by
injections of ACh and/or EM in symptomatic patients with
Brugada syndrome. The data suggest that the coexistence of
vasospastic angina was not rare (11%) in symptomatic
patients with Brugada syndrome. The coexistence of Bru-
gada syndrome and vasospastic angina is clinically impor-
tant, especially from a therapeutic point of view. The first
line of therapy for vasospastic angina is administration of
calcium antagonists or nitrates, which also have a blocking
action of ICa. The use of these agents in patients with
vasospastic angina would be expected to attenuate ST-
Figure 1. Twelve-lead electrocardiogram (ECG) in the baseline condition (A), after injection of 50 g acetylcholine (ACh) into the right coronary artery
(B), and after ventricular fibrillation (VF) induction by ACh (C) in a patient with Brugada syndrome. The baseline ECG shows coved or saddle-back type
ST-segment elevation in leads V1 and V2. Injection of ACh augmented the ST-segment elevation in leads V1 and V2 (B, arrows), without any induction
of coronary spasm, resulting in spontaneously induced VF.
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Figure 3. Twelve-lead electrocardiogram in the baseline condition (A), after injection of 50 g acetylcholine (ACh) into the right coronary artery (B), and
after injection of 40 g ergonovine maleate (EM) into the right coronary artery (C) in a patient with Brugada syndrome. Injection of ACh augmented the
ST-segment elevation in leads V1 and V2, without any induction of coronary spasm (B, arrows), whereas injection of EM did not change the ST-segment
elevation.
Figure 2. Twelve-lead electrocardiogram in the baseline condition (A) and after injection of 40 g ergonovine maleate (EM) into the right coronary artery
(B) in a control subject. Injection of EM produced right coronary spasm (segment no. 2, 75%; segment no. 4, 100%), associated with ST-segment elevation
in leads II, III, and aVF (B, arrows). However, no ST-segment elevation was observed in leads V1 to V3, like that in patients with Brugada syndrome (B,
arrows).
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segment elevation in the right precordial leads and to induce
VF as a result of ICa inhibition—that is, if the patients were
associated with Brugada syndrome. Therefore, the coexist-
ence of Brugada syndrome and vasospastic angina should
always be taken into account for the management of both
patients with Brugada syndrome and those with vasospastic
angina.
Possible mechanism of augmentation of ST-segment
elevation in the right precordial leads and VF by intra-
coronary injection of ACh and/or EM. Yan and Ant-
zelevitch (12,13) developed an experimental model of Bru-
gada syndrome by using arterially perfused canine right
ventricular wedge preparations, and they suggested that
heterogeneous repolarization across the ventricular wall of
the RVOT was responsible for the ST-segment elevation
and the genesis of VF in Brugada syndrome. They used
several autonomic and anti-arrhythmic agents in their mod-
els and suggested that any agents that increase outward
currents (Ito or IKATP) or decrease inward currents (ICa or
fast INa) can increase the magnitude of the action potential
notch, resulting in ST-segment elevation and VF in patients
with Brugada syndrome. So far, this hypothesis most likely
explains the clinical manifestation, such as responses to
autonomic agonists (e.g., isoproterenol, ACh) and antago-
nists (e.g., beta-blockers, atropine) or sodium channel
blockers in patients with Brugada syndrome (16–23). In the
present study, ST-segment elevation in leads V1 to V3 was
augmented by the right coronary injection of ACh or EM,
without any visible coronary spasm in one-third of the
symptomatic patients with Brugada syndrome, but not in
any of the control subjects. Of note, the left coronary
injection of ACh or EM could never attenuate the ST-
segment elevation in leads V1 to V3, even in patients with
Brugada syndrome. These findings suggest that the Ito-
mediated phase 1 notch of the epicardial cells in the RVOT
was sensitive to vagal stimulation (decrease in ICa) produced
by ACh or to mild ischemia (increase in IKATP and/or
decrease in ICa), which was induced by EM but was not able
to cause visible coronary spasm, thus resulting in the
augmentation of ST-segment elevation in the right precor-
dial leads. Augmentation of ST-segment elevation was
more easily induced by the right coronary injection of ACh
versus EM (55% vs. 23%). Moreover, ST-segment elevation
in leads V1 to V3 was augmented by four of six right
coronary injections of ACh, but by only one of six right
coronary injections of EM in six patients with Brugada
syndrome in whom both ACh and EM were used. These
data indicate that suppression of ICa by vagal stimulation
with ACh played a more significant role in the mechanism
of augmentation of ST-segment elevation in Brugada syn-
drome.
Ventricular fibrillation was induced after augmentation of
ST-segment elevation in the right precordial leads by three
right coronary injections of ACh or EM, but not by any left
coronary injections. These results indicate a correlation
between prominent ST-segment elevation and subsequent
VF and support the hypothesis of VF due to phase 2 reentry
(24,25).
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